Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

Authors :: Sanne, Ian
Piliero, Peter
Squires, Kathleen
Thirty, Alexandra
Schnittman, Steven
Source :: Journal of Acquired Immune Deficiency Syndromes (1999). Jan, 2003, Vol. 32 Issue 1, p18, 10 p.
Publication Year :: 2003
Abstract: Research has been conducted on protease inhibitor atazanavir. The dose levels of this medication have been compared with those of nelfinavir as a monotherapy and in combination with didanosine and stavudine, and the results of this clinical trial carried out to compare safety, tolerability and antiretroviral efficacy of these three doses are reported.

Subjects :: Clinical trials -- Comparative analysis
Stavudine -- Dosage and administration
Stavudine -- Physiological aspects
Didanosine -- Dosage and administration
Didanosine -- Physiological aspects
Drug therapy -- Analysis
Drug therapy -- Usage
Epidemiology -- Statistics
Epidemiology -- Research
HIV patients -- Drug therapy
HIV patients -- Health aspects
HIV patients -- Care and treatment
HIV infection -- Prevention
HIV infection -- Research
HIV infection -- Health aspects
Antiviral agents -- Dosage and administration
Antiviral agents -- Physiological aspects
AIDS (Disease) -- Research
Health

Tools